Free Trial

Insmed (INSM) Competitors

Insmed logo
$102.56 -1.61 (-1.55%)
Closing price 04:00 PM Eastern
Extended Trading
$102.74 +0.17 (+0.17%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INSM vs. TAK, ARGX, BNTX, ONC, TEVA, SMMT, ITCI, GMAB, RDY, and MRNA

Should you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Takeda Pharmaceutical (TAK), argenex (ARGX), BioNTech (BNTX), BeOne Medicines (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

Insmed vs. Its Competitors

Takeda Pharmaceutical (NYSE:TAK) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Takeda Pharmaceutical has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Takeda Pharmaceutical has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.09B1.53$712.33M$0.2265.55
Insmed$363.71M53.49-$913.77M-$5.95-17.24

In the previous week, Insmed had 15 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 19 mentions for Insmed and 4 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.10 beat Insmed's score of 1.01 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Takeda Pharmaceutical
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Insmed
14 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 3.0% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Takeda Pharmaceutical has a net margin of 2.36% compared to Insmed's net margin of -265.93%. Takeda Pharmaceutical's return on equity of 10.64% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Takeda Pharmaceutical2.36% 10.64% 5.14%
Insmed -265.93%-446.98%-52.70%

Insmed has a consensus price target of $108.47, suggesting a potential upside of 5.76%. Given Insmed's higher probable upside, analysts plainly believe Insmed is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Takeda Pharmaceutical
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Insmed
0 Sell rating(s)
0 Hold rating(s)
17 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Takeda Pharmaceutical beats Insmed on 9 of the 15 factors compared between the two stocks.

Get Insmed News Delivered to You Automatically

Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INSM vs. The Competition

MetricInsmedMED IndustryMedical SectorNASDAQ Exchange
Market Cap$19.76B$2.96B$5.54B$9.41B
Dividend YieldN/A2.46%3.75%4.03%
P/E Ratio-17.248.2821.0120.09
Price / Sales53.49303.17433.8199.01
Price / CashN/A42.5936.1658.27
Price / Book64.107.678.125.65
Net Income-$913.77M-$55.28M$3.25B$257.91M
7 Day Performance4.46%2.50%0.97%2.09%
1 Month Performance3.12%11.70%7.36%11.13%
1 Year Performance36.64%4.89%31.31%18.40%

Insmed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INSM
Insmed
3.8659 of 5 stars
$102.56
-1.5%
$108.47
+5.8%
+37.9%$19.76B$363.71M-17.241,271Positive News
Analyst Forecast
Insider Trade
TAK
Takeda Pharmaceutical
2.0054 of 5 stars
$15.07
-1.8%
N/A+7.6%$47.95B$30.09B68.5047,455Positive News
ARGX
argenex
4.4966 of 5 stars
$546.04
+0.5%
$728.06
+33.3%
+23.6%$33.34B$2.25B33.691,599Positive News
Analyst Revision
BNTX
BioNTech
1.4591 of 5 stars
$110.05
+0.0%
$137.86
+25.3%
+28.4%$26.45B$2.98B-32.376,772Analyst Forecast
ONC
BeOne Medicines
2.5583 of 5 stars
$240.99
-1.8%
$320.67
+33.1%
N/A$26.41B$4.18B-64.7811,000Analyst Forecast
Gap Up
TEVA
Teva Pharmaceutical Industries
4.1195 of 5 stars
$16.84
-1.0%
$24.13
+43.3%
-0.4%$19.31B$16.54B-14.6436,830
SMMT
Summit Therapeutics
2.886 of 5 stars
$22.61
-7.9%
$34.67
+53.3%
+196.8%$16.79B$700K-66.50110
ITCI
Intra-Cellular Therapies
0.9225 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
3.9168 of 5 stars
$20.52
+1.1%
$37.60
+83.2%
-18.0%$13.16B$3.12B11.662,682Analyst Revision
RDY
Dr. Reddy's Laboratories
2.7536 of 5 stars
$15.08
flat
$16.95
+12.4%
-6.6%$12.59B$3.81B22.8527,811News Coverage
Upcoming Earnings
MRNA
Moderna
4.2835 of 5 stars
$29.90
-1.9%
$46.61
+55.9%
-74.0%$11.56B$3.24B-3.425,800Trending News
Options Volume
Analyst Revision

Related Companies and Tools


This page (NASDAQ:INSM) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners